Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 257

1.

Immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus.

Barbosa CM, Terreri MT, Rosário PO, de Moraes-Pinto MI, Silva CA, Hilário MO.

Clin Exp Rheumatol. 2012 Sep-Oct;30(5):791-8. Epub 2012 Oct 17.

PMID:
22935227
2.

Evaluation of varicella zoster virus-specific cell-mediated immunity by using an interferon-γ enzyme-linked immunosorbent assay.

Hayashida K, Ozaki T, Nishimura N, Gotoh K, Funahashi K, Nakane K, Gomi Y, Manabe S, Ishikawa T, Yamanishi K.

J Immunol Methods. 2015 Nov;426:50-5. doi: 10.1016/j.jim.2015.07.011. Epub 2015 Jul 29.

PMID:
26232696
3.

Altered cellular and humoral immunity to varicella-zoster virus in patients with autoimmune diseases.

Rondaan C, de Haan A, Horst G, Hempel JC, van Leer C, Bos NA, van Assen S, Bijl M, Westra J.

Arthritis Rheumatol. 2014 Nov;66(11):3122-8. doi: 10.1002/art.38804.

4.

Herpes zoster vaccination in SLE: a pilot study of immunogenicity.

Guthridge JM, Cogman A, Merrill JT, Macwana S, Bean KM, Powe T, Roberts V, James JA, Chakravarty EF.

J Rheumatol. 2013 Nov;40(11):1875-80. doi: 10.3899/jrheum.130170. Epub 2013 Sep 15.

5.

Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005-2009.

Weinmann S, Chun C, Schmid DS, Roberts M, Vandermeer M, Riedlinger K, Bialek SR, Marin M.

J Infect Dis. 2013 Dec 1;208(11):1859-68. doi: 10.1093/infdis/jit405. Epub 2013 Aug 6.

PMID:
23922376
6.

Reduced varicella-zoster-virus (VZV)-specific lymphocytes and IgG antibody avidity in solid organ transplant recipients.

Prelog M, Schönlaub J, Jeller V, Almanzar G, Höfner K, Gruber S, Eiwegger T, Würzner R.

Vaccine. 2013 May 7;31(20):2420-6. doi: 10.1016/j.vaccine.2013.03.058. Epub 2013 Apr 10.

PMID:
23583889
7.

A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella.

Gershon AA, Levin MJ, Weinberg A, Song LY, LaRussa PS, Steinberg SP, Bartlett P; Pediatric AIDS Clinical Trials Group 391 Team.

Pediatr Infect Dis J. 2009 Jul;28(7):653-5. doi: 10.1097/INF.0b013e3181998f06.

8.

Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies.

Parrino J, McNeil SA, Lawrence SJ, Kimby E, Pagnoni MF, Stek JE, Zhao Y, Chan IS, Kaplan SS.

Vaccine. 2017 Mar 27;35(14):1764-1769. doi: 10.1016/j.vaccine.2016.10.055. Epub 2017 Mar 3.

PMID:
28268074
9.

Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany.

Wiese-Posselt M, Siedler A, Mankertz A, Sauerbrei A, Hengel H, Wichmann O, Poethko-Müller C.

BMC Infect Dis. 2017 May 19;17(1):356. doi: 10.1186/s12879-017-2461-2.

10.

Cellular immune response of a varicella vaccine following simultaneous DTaP and VZV vaccination.

Habermehl P, Lignitz A, Knuf M, Schmitt HJ, Slaoui M, Zepp F.

Vaccine. 1999 Feb 26;17(7-8):669-74.

PMID:
10067672
11.

Association of reduced CD4 T cell responses specific to varicella zoster virus with high incidence of herpes zoster in patients with systemic lupus erythematosus.

Park HB, Kim KC, Park JH, Kang TY, Lee HS, Kim TH, Jun JB, Bae SC, Yoo DH, Craft J, Jung S.

J Rheumatol. 2004 Nov;31(11):2151-5.

PMID:
15517626
12.

Altered phenotype and functionality of varicella zoster virus-specific cellular immunity in individuals with active infection.

Schub D, Janssen E, Leyking S, Sester U, Assmann G, Hennes P, Smola S, Vogt T, Rohrer T, Sester M, Schmidt T.

J Infect Dis. 2015 Feb 15;211(4):600-12. doi: 10.1093/infdis/jiu500. Epub 2014 Sep 1.

PMID:
25180236
13.

Immunogenicity of a two-dose regime of varicella vaccine in children with cancers.

Leung TF, Li CK, Hung EC, Chan PK, Mo CW, Wong RP, Chik KW.

Eur J Haematol. 2004 May;72(5):353-7.

PMID:
15059071
14.

Restoration of varicella-zoster virus cell-mediated immune response after varicella booster vaccination.

Berger R, Luescher D, Just M.

Postgrad Med J. 1985;61 Suppl 4:143-5.

PMID:
3014472
15.

[Herpes zoster after varicella-zoster vaccination].

Fahlbusch M, Wesselmann U, Lehmann P.

Hautarzt. 2013 Feb;64(2):107-9. doi: 10.1007/s00105-012-2477-x. German.

PMID:
23358727
16.

Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine.

Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ, Irwin MR, Clair J, Smith JG, Stanley H, Marchese RD, Harbecke R, Williams HM, Chan IS, Arbeit RD, Gershon AA, Schödel F, Morrison VA, Kauffman CA, Straus SE, Schmader KE, Davis LE, Levin MJ; US Department of Veterans Affairs (VA) Cooperative Studies Program Shingles Prevention Study Investigators.

J Infect Dis. 2009 Oct 1;200(7):1068-77. doi: 10.1086/605611.

17.

Low induction of varicella-zoster virus-specific secretory IgA antibody after vaccination.

Terada K, Niizuma T, Yagi Y, Miyashima H, Kataoka N, Sadahiro T.

J Med Virol. 2000 Sep;62(1):46-51.

PMID:
10935988
18.

Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.

Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, Caulfield MJ, Irwin MR, Smith JG, Clair J, Chan IS, Williams H, Harbecke R, Marchese R, Straus SE, Gershon A, Weinberg A; Veterans Affairs Cooperative Studies Program Shingles Prevention Study Investigators.

J Infect Dis. 2008 Mar 15;197(6):825-35. doi: 10.1086/528696.

19.

Vaccination to prevent varicella: Goldman and King's response to Myers' interpretation of Varicella Active Surveillance Project data.

Goldman GS, King PG.

Hum Exp Toxicol. 2014 Aug;33(8):886-93. doi: 10.1177/0960327113512340. Epub 2013 Nov 25.

Supplemental Content

Support Center